XV International HIV Drug Resistance Workshop
Selected Slide Presentations Click on the links below to view presentations.
Plenary New Achievements in Hepatitis C Virus Research and Their Implications for Antiviral Therapy Ralf Bartenschlager, University of Heidelberg, Germany
HCV Drug Resistance Synergy of Small Molecular Inhibitors of Hepatitis C Virus (HCV) Replication Directed at Different Viral Targets David Wyles, UCSD, USA
Selection and Characterization of Hepatitis C Virus Replicon Variants Dually Resistant to Thumb and Palm Binding Non-Nucleoside Polymerase Inhibitors Isabel Najera, Roche Palo Alto, USA
Resistance to New Antiretroviral Agents Identification and Characterization of Novel Reverse Transcriptase Inhibitors Miguel Quinones-Mateu, Cleveland Clinic Foundation, USA
The In Vitro Resistance Profile of NcRTI-1 is Complementary with the Resistance Profile of Tenofovir and Zidovudine Dirk Jochmans, Tibotec, Belgium
HIV Pathogenesis, Fitness and Resistance HBV Drug Resistance Stephen Locarnini, Victorian Infectious Diseases Reference Laboratory, Australia
Sequential Emergence and Clinical Implications of K70E and K65R Viral Mutants during Prolonged Tenofovir Monotherapy in Rhesus Macaques with Chronic RT-SHIV Infection Koen Van Rompay, California National Primate Research Center, USA
Selection of Non-Nucleoside Reverse Transcriptase Inhibitor (NNRTI) Resistant HIV-1 after Discontinuation of a Virologically Suppressive Regimen Brad Hare, University of California, San Francisco, USA
Impact of Enfuvirtide Resistance Genotype on CD4 Increases in Patients with Ongoing Viral Replication while Receiving Enfuvirtide Tom Melby, Trimeris, Inc., USA
Clinical Implications of Resistance Allele-Specific PCR Shows Low-Level K65R in Treatment-Experienced Patients with L74V in the Absence of TAMs Michael Miller, Gilead Sciences, USA
Defining Lower (L) and Upper (U) Phenotypic Clinical Cutoffs (CCOâ??s) for Tipranavir (TPV), Lopinavir (LPV), Saquinavir (SQV) and Amprenavir (APV) Co-administered with Ritonavir (r) within the RESIST Dataset using the PhenoSense Assay (Monogram (MGRM) Biosciences) Eoin Coakley, Monogram Biosciences, USA
Mechanisms of HIV Drug Resistance The HIV-1 Reverse Transcriptase Connection Domain From Treatment-Experienced Patients Contributes to AZT Resistance Krista Frankenberry, HIV Drug Resistance Program, USA
Infrequent Occurrence of Mutations in the C-terminal Region of Reverse Transcriptase Modulates Susceptibility to RT Inhibitors Soumi Gupta, Monogram Biosciences Inc., USA
Invited Session: Resistance Test Interpretation & Prediction of Clinical Response Rules & Algorithms, Derivation, Deviation and Validation Jonathan Schapiro, National Hemophilia Center, Israel
|